Cogent Biosciences director granted 17,901 options
Cogent Biosciences director Todd Shegog received a new stock option award covering 17,901 shares of common stock.
Rhea-AI Filing Summary
Cogent Biosciences director Todd Shegog received a new stock option award covering 17,901 shares of common stock. The options have an exercise price of $31.98 per share and expire on June 9, 2036. This grant increases his direct derivative holdings to 17,901 option shares.
The option will vest in full on the earlier of the first anniversary of the grant date or the date of the company’s 2027 Annual Meeting of Stockholders, provided Shegog continues to serve the company through that date. Until vesting and exercise, the award represents potential, not current, share ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 17,901 shares
Grant/Award
1 txn
Insider
Shegog Todd
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 17,901 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 17,901 contracts (Direct)
Footnotes (1)
- F1. This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.
Key Figures
Option grant size: 17,901 shares
Exercise price: $31.98 per share
Expiration date: June 9, 2036
+1 more
4 metrics
Option grant size
17,901 shares
Stock options granted to director on June 9, 2026
Exercise price
$31.98 per share
Strike price for the 17,901 stock options
Expiration date
June 9, 2036
Option term for director grant
Post-grant derivative holdings
17,901 option shares
Total derivative securities following this grant
Key Terms
Stock Option (Right to Buy), exercise price, Annual Meeting of Stockholders, vesting
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "31.9800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Annual Meeting of Stockholders financial
"the date of the 2027 Annual Meeting of Stockholders"
vesting financial
"This stock option shall vest in full upon the earlier of the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Todd Shegog report in his latest Form 4 for COGT?
Todd Shegog reported receiving a stock option grant for 17,901 shares of Cogent Biosciences common stock. The options are a compensation-related award, not an open-market purchase or sale of existing shares.
How many Cogent Biosciences options did Todd Shegog receive?
Todd Shegog received stock options covering 17,901 shares of Cogent Biosciences common stock. These options give him the right to buy shares in the future once they vest and are exercised, subject to the grant’s terms.
What is the exercise price of Todd Shegog’s Cogent Biosciences options?
The exercise price of Todd Shegog’s stock options is $31.98 per share. This is the price he must pay to purchase Cogent Biosciences common stock once the options vest and he chooses to exercise them, before their expiration date.
When do Todd Shegog’s Cogent Biosciences options vest?
The options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders. Vesting is contingent on Todd Shegog’s continued service with Cogent Biosciences through that vesting date.
When do Todd Shegog’s Cogent Biosciences stock options expire?
Todd Shegog’s stock options expire on June 9, 2036. If he does not exercise the options by that expiration date, they lapse and can no longer be used to purchase Cogent Biosciences common shares under this grant.
Is Todd Shegog’s Form 4 for COGT an open-market trade?
No, the Form 4 reflects a grant of stock options as compensation, coded as an acquisition (A). It does not involve an open-market purchase or sale of Cogent Biosciences shares, but rather an award of rights to buy shares later.
AI-generated analysis. How Rhea-AI works. Not financial advice.
